ABSTRACT
Present address: Elizabeth A. Lakota, Vertex Pharmaceuticals, Boston, Massachusetts, USA.Present address: Justin C. Bader, Bicycle Therapeutics, Lexington, Massachusetts, USA.Present address: Catharine C. Bulik, Food and Drug Administration, Silver Spring, Maryland, USA.Present address: Lawrence Friedrich, AN2 Theraputics, Menlo Park, California, USA.Present address: Judith N. Steenbergen, Scientific and Medical Affairs Consulting, LLC, Newtown, Pennsylvania, USA.The authors declare a conflict of interest. S.M.B., J.P.H., M.T., B.D.V., C.M.R. and P.G.A. are employees of the Institute for Clinical Pharmacodynamics, Inc., which has received research support from Paratek Pharmaceuticals, Inc. E.A.L. was an employee of ICPD at the time the analyses were conducted and is currently an employee of Vertex Pharmaceuticals. J.C.B. was an employee of ICPD at the time the analyses were conducted and is currently an employee of Bicycle Therapeutics. C.C.B. was an employee of ICPD at the time the analyses were conducted and is currently an employee of the Food and Drug Administration. L.F. was an employee of Paratek Pharmaceuticals at the time the analyses were conducted and is currently and employee of AN2 Therapeutics. M.D.H. is an employee of JMI Laboratories, which has received research support from Paratek Pharmaceuticals, Inc. J.N.S. was an employee of Paratek Pharmaceuticals at the time the analyses were conducted and is currently an employee of Scientific and Medical Affairs Consulting, LLC.Omadacycline, a novel aminomethylcycline with 